<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085821</url>
  </required_header>
  <id_info>
    <org_study_id>IRR-CLP-2019-4</org_study_id>
    <nct_id>NCT05085821</nct_id>
  </id_info>
  <brief_title>Cardio-visual Stimulation in Augmented Reality for Pain Reduction</brief_title>
  <acronym>HEART</acronym>
  <official_title>Cardio-visual Stimulation in Augmented Reality for Pain Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mindmaze SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the feasibility and efficacy of an Augmented&#xD;
      Reality (AR) biofeedback intervention to alleviate pain symptoms in individuals suffering&#xD;
      from chronic pain of the hand and/or the forearm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pain is a major public health problem with implications for high health care costs,&#xD;
      lost productivity and an estimated financial burden of $500 billion. Individuals with chronic&#xD;
      pain are also at an increased risk of developing an opioid use disorder.&#xD;
&#xD;
      Chronic pain has previously been associated with a distorted body representation, in&#xD;
      particular of the affected body parts. Virtual Reality (VR) studies using embodiment-,&#xD;
      respiration-, and heart-beat related feedback have demonstrated positive effects for induced&#xD;
      pain in healthy participants (e.g., increased pain thresholds) and chronic pain in patient&#xD;
      populations (e.g., decreased subjective pain, improved functionality, improved physiological&#xD;
      markers of pain). Based on these studies, the AR intervention evaluated here aims to&#xD;
      alleviate subjective pain symptoms and improve physiological pain markers in chronic pain&#xD;
      patients using heartbeat-related feedback.&#xD;
&#xD;
      This within-subject study will compare subjective pain ratings before, during, and after an&#xD;
      AR intervention that provides visual feedback of participants' on-going heartbeat in relation&#xD;
      to their affected limb. Primary outcomes include subjective reports from participants&#xD;
      (perceived efficacy, acceptability, and demand) and the intervention's clinical feasibility,&#xD;
      including reports from therapists. Secondary outcomes include changes in heart rate and&#xD;
      variability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in perceived pain</measure>
    <time_frame>change in pain rating will be evaluated when participants first wear the Head-Mounted Display (baseline), after 3 minutes of video-passthrough (Pre), after 3 minutes of cardio-visual stimulation (post), after 3 minutes of video-passthrough (final)</time_frame>
    <description>The patient moves a cursor on a Visual Analog Scale to indicate their currently perceived level of pain. The gauge ranges from &quot;no pain&quot; (0) to &quot;worst pain imaginable&quot; (10).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Heart-Rate Variability (time domain)</measure>
    <time_frame>a change in heart-rate variability will be evaluated between baseline (pre), intervention, and immediately following intervention (post)</time_frame>
    <description>time-domain metrics of heart-rate variability [ms]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Heart-Rate Variability (frequency domain)</measure>
    <time_frame>a change in heart-rate variability will be evaluated between baseline (pre), intervention, and immediately following intervention (post)</time_frame>
    <description>frequency-domain metric of heart-rate variability (power)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>The first day of the study</time_frame>
    <description>Questionnaire on the sensations, usability, and satisfaction with the augmented reality stimulation using a Visual Analog Scale (0-10) where higher scores indicate agreement with the questionnaire item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>The second day of the study</time_frame>
    <description>Questionnaire on the sensations, usability, and satisfaction with the augmented reality stimulation using a Visual Analog Scale (0-10) where higher scores indicate agreement with the questionnaire item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>The third day of the study</time_frame>
    <description>Questionnaire on the sensations, usability, and satisfaction with the augmented reality stimulation using a Visual Analog Scale (0-10) where higher scores indicate agreement with the questionnaire item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>The fourth day of the study</time_frame>
    <description>Questionnaire on the sensations, usability, and satisfaction with the augmented reality stimulation using a Visual Analog Scale (0-10) where higher scores indicate agreement with the questionnaire item.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Regional Pain Syndrome</condition>
  <condition>Chronic Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental 1: HEART - Placebo - HEART - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient receives visual feedback in an augmented reality environment in four session, over two weeks.&#xD;
Week 1: HEART, Placebo (after &gt;24hour washout) Week 2: HEART, Placebo (after &gt;24hour washout)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2: HEART - Placebo - Placebo - HEART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient receives visual feedback in an augmented reality environment in four session, over two weeks.&#xD;
Week 1: HEART, Placebo (after &gt;24hour washout) Week 2: Placebo, HEART (after &gt;24hour washout)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3: Placebo - HEART - Placebo - HEART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient receives visual feedback in an augmented reality environment in four session, over two weeks.&#xD;
Week 1: Placebo, HEART (after &gt;24hour washout) Week 2: Placebo, HEART (after &gt;24hour washout)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 4: Placebo - HEART - HEART - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient receives visual feedback in an augmented reality environment in four session, over two weeks.&#xD;
Week 1: HEART, Placebo (after &gt;24hour washout) Week 2: Placebo, HEART (after &gt;24hour washout)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HEART</intervention_name>
    <description>In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)</description>
    <arm_group_label>Experimental 1: HEART - Placebo - HEART - Placebo</arm_group_label>
    <arm_group_label>Experimental 2: HEART - Placebo - Placebo - HEART</arm_group_label>
    <arm_group_label>Experimental 3: Placebo - HEART - Placebo - HEART</arm_group_label>
    <arm_group_label>Experimental 4: Placebo - HEART - HEART - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)</description>
    <arm_group_label>Experimental 1: HEART - Placebo - HEART - Placebo</arm_group_label>
    <arm_group_label>Experimental 2: HEART - Placebo - Placebo - HEART</arm_group_label>
    <arm_group_label>Experimental 3: Placebo - HEART - Placebo - HEART</arm_group_label>
    <arm_group_label>Experimental 4: Placebo - HEART - HEART - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be over 18 years of age&#xD;
&#xD;
          -  Present permanent chronic pain (for more than 3 months), secondary to a peripheral&#xD;
             pathology (traumatic, orthopedic or neurological), located in the hand or forearm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  People in emergency situations&#xD;
&#xD;
          -  Persons unable to give informed consent&#xD;
&#xD;
          -  Persons who are mentally or linguistically unable to understand the research test&#xD;
             instructions&#xD;
&#xD;
          -  Individuals who are not available to complete the entire study protocol&#xD;
&#xD;
          -  Cognitive impairments that prevent the use of the equipment&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Patients with seizure disorders&#xD;
&#xD;
          -  Patients with central hemineglect&#xD;
&#xD;
          -  Pain secondary to central nervous system pathology&#xD;
&#xD;
          -  Patients with arrhythmia&#xD;
&#xD;
          -  Patients with head tremors or head shaking.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Paysant, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UGECAM Nord Est</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Pierret, PhD</last_name>
    <phone>03 83 52 67 61</phone>
    <email>jonathan.pierret@ugecam.assurance-maladie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Régional de Médecine Physique et de Réadaptation</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie Touillet, Md</last_name>
      <phone>+33 3 82 52 6761</phone>
      <email>amelie.touillet@ugecam.assurance-maladie.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Pierret, PhD</last_name>
      <phone>+33 3 82 52 6761</phone>
      <email>jonathan.pierret@ugecam.assurance-maladie.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est</investigator_affiliation>
    <investigator_full_name>Amélie Touillet</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

